Walter G. Lohr Sells 3,906 Shares of Danaher Co. (NYSE:DHR) Stock

Danaher Co. (NYSE:DHR – Get Rating) Director Walter G. Lohr sold 3,906 shares of the company’s stock in a transaction on Friday, July 22nd. The stock was sold at an average price of $273.84, for a total transaction of $1,069,619.04. Following the completion of the transaction, the director now owns 12,115 shares of the company’s stock, valued at $3,317,571.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Danaher Trading Down 0.2 %

Shares of DHR stock opened at $273.38 on Tuesday. Danaher Co. has a 12-month low of $233.71 and a 12-month high of $333.96. The company has a current ratio of 1.75, a quick ratio of 1.32 and a debt-to-equity ratio of 0.45. The firm’s 50 day moving average is $255.77 and its 200 day moving average is $268.61. The stock has a market capitalization of $198.77 billion, a P/E ratio of 32.20, a P/E/G ratio of 2.22 and a beta of 0.83.

Danaher (NYSE:DHR – Get Rating) last issued its quarterly earnings results on Thursday, July 21st. The conglomerate reported $2.76 earnings per share for the quarter, topping the consensus estimate of $2.35 by $0.41. The business had revenue of $7.75 billion for the quarter, compared to analysts’ expectations of $7.29 billion. Danaher had a net margin of 20.61% and a return on equity of 18.57%. The company’s revenue was up 7.4% compared to the same quarter last year. During the same quarter last year, the company posted $2.46 EPS. Research analysts expect that Danaher Co. will post 10.29 earnings per share for the current year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, July 29th. Shareholders of record on Friday, June 24th will be issued a $0.25 dividend. The ex-dividend date of this dividend is Thursday, June 23rd. This represents a $1.00 dividend on an annualized basis and a yield of 0.37%. Danaher’s dividend payout ratio is currently 11.78%.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Wells Fargo & Company lowered shares of Danaher from an “overweight” rating to an “equal weight” rating and dropped their target price for the stock from $330.00 to $265.00 in a report on Monday, April 25th. Cowen decreased their target price on shares of Danaher to $340.00 in a research note on Friday. KeyCorp decreased their target price on shares of Danaher from $345.00 to $325.00 and set an “overweight” rating for the company in a research note on Friday. Barclays raised their target price on shares of Danaher from $290.00 to $310.00 in a research note on Friday. Finally, Royal Bank of Canada increased their price target on shares of Danaher from $301.00 to $317.00 in a report on Friday. One equities research analyst has rated the stock with a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $327.00.

Institutional Trading of Danaher

Institutional investors and hedge funds have recently bought and sold shares of the stock. Steward Financial Group LLC increased its holdings in Danaher by 330.4% in the 2nd quarter. Steward Financial Group LLC now owns 99 shares of the conglomerate’s stock valued at $25,000 after acquiring an additional 76 shares during the last quarter. GHP Investment Advisors Inc. purchased a new position in shares of Danaher during the 1st quarter worth about $26,000. Lloyd Advisory Services LLC. purchased a new stake in Danaher in the 1st quarter valued at about $26,000. Maryland Capital Advisors Inc. purchased a new stake in Danaher in the 4th quarter valued at about $28,000. Finally, Dixon Hughes Goodman Wealth Advisors LLC purchased a new stake in Danaher in the 4th quarter valued at about $29,000. 78.42% of the stock is currently owned by institutional investors.

Danaher Company Profile

(Get Rating)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy.